Figure 1: Antitumor effects of the nanoparticles in vivo. (IMAGE)
Caption
(A) Tumor growth profiles after the different treatments (mean ± SD, n = 4). The subcutaneous tumor model of hepatocellular carcinoma (HCC) was established by injecting 1 × 107 HepG2 cells subcutaneously into the right leg of female BALB/c nude mice aged 4-5 weeks. Once the tumor volume reached approximately 50 mm³, the mice were randomly divided into five groups: PBS, DOX, FDH, FDAP, and FDAH. Nanoparticles were administered intravenously every two days at a dose equivalent to 10 mg/kg of DOX. Tumor growth and body weight were monitored every two days. (B) The inhibition rate of the tumor after the different treatments (mean ± SD, n = 4). (C) Photos of the tumors excised from the mice after the different treatments. (D) The weight of the tumors excised from the mice after the different treatments (mean ± SD, n = 4). #, P < 0.05; ##, P < 0.01 between indicated group and PBS group; ∗, P < 0.05; ∗∗, P < 0.01 between indicated groups. (E) H&E staining of the excised tumors after the different treatments. Scale bar = 200 μm.
Credit
Guo C, Dou R, Wang L B, et al.
Usage Restrictions
Credit must be given to the creator. Only noncommercial uses of the work are permitted. No derivatives or adaptations of the work are permitted.
License
CC BY-NC-ND